05:15 PM EDT, 07/01/2024 (MT Newswires) -- HOOKIPA Pharma ( HOOK ) said Monday the first person has been dosed in its phase 1b study of its investigational vaccine HB-500 for the treatment of HIV.

The study will evaluate safety and tolerability, reactogenicity, and immunogenicity of continued doses of the vaccine in patients with HIV on suppressive antiretroviral treatment, according to the company.

HOOKIPA said it will receive a $5 million non-dilutive milestone payment as part of its collaboration and license agreement with Gilead (GILD). HOOKIPA is responsible for advancing the HIV program through the completion of a phase 1b trial.

Shares of the company were down almost 2% in after-hours trading.

Price: 0.6164, Change: -0.01, Percent Change: -1.89